Fig. 1.

(A) Effects of the administration of mosapride citrate on gastric transit time (GTT). The GTT was significantly shorter in the mosapride group than in the control (p=0.02). The median GTT was 30 minutes in the mosapride administration group and 56 minutes in the non-administration group. The data are presented in a box-and-whisker plot. The box includes those results falling between the 25th and 75th percentiles, and the median value is represented as a horizontal line inside the box (outliers and extremes are not shown). (B) Effects of the administration of mosapride citrate on small bowel transit time (SBTT). The SBTT of the capsule was significantly shorter in the mosapride group compared with the control (p=0.01). The median SBTT was 231 minutes in the mosapride administration group and 279 minutes in the non-administration group. The data are presented in a box-and-whisker plot. The box includes those results falling between 25th and 75th percentiles, and the median value is represented as a horizontal line inside the box (outliers and extremes are not shown).